Dependence on a Small Number of Partner Companies and Risk of Contract Termination
First written in FY2016. 25 of 28 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 8 of 42 companies on the "Worse" side.
8 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「The company also terminated its licensing agreement with Stemline for CBS9106, which had continued since December 2014, and now holds all rights itself.」
Although the agreement with Stemline has ended, the company is no longer dependent on that agreement and now holds the rights to CBS9106 itself. - FY2025MaterialisedAnnual report
「In June 2025, all rights were returned to the company.」
The risk of termination of the licence agreement with Stemline materialised, with the agreement being terminated and all rights returned to the company. This eliminated its dependence on the agreement, while leaving the company to reconsider the development and commercialisation of CBS9106. - FY2025-H1RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's future profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk that termination of the agreement will affect future profit or loss. - FY2024-Q3RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's future profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk that termination of the agreement will affect future profit or loss. - FY2024-Q1RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's future profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk that termination of the agreement will affect future profit or loss. - FY2023RestatedAnnual report
「For CBS9106, the company entered into a licence agreement with Stemline in December 2014 granting exclusive worldwide rights, initially excluding Japan, China, Taiwan and South Korea, for its development, manufacture and commercialisation. In August 2018, the agreement was amended to remove these excluded territories. Based on this strategic partnership, the company selected a development structure involving relatively lower risk for the company.」
The company continues to use a development structure for CBS9106 that depends on Stemline's worldwide licence and a business structure based on a partnership agreement. - FY2023-Q3RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's future profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk that termination of the agreement will affect future profit or loss. - FY2023-Q2RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's future profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on future profit or loss if the agreement is terminated. - FY2022RestatedAnnual report
「The company will continue alliance activities with pharmaceutical companies and similar entities for subsequent pipeline products developed in the future in an effort to diversify business risks. However, given its business model, the situation is expected to continue for an extended period in which its business plan depends on contracts with a limited number of partners.」
Reconfirms the risk that dependence on a small number of partners will continue over the long term, despite advancing partnership activities for subsequent pipeline products. - FY2022-Q3RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2022-Q2RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2021RestatedAnnual report
「The company will continue alliance activities with pharmaceutical companies and similar entities for subsequent pipeline products developed in the future in an effort to diversify business risks. However, given its business model, the situation is expected to continue for an extended period in which its business plan depends on contracts with a limited number of partners.」
Reconfirms the risk that dependence on a small number of partners will continue over the long term, despite advancing partnership activities for subsequent pipeline products. - FY2021-Q3RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2021-Q2RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2021-Q1RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2020RestatedAnnual report
「The company will continue alliance activities with pharmaceutical companies and similar entities for subsequent pipeline products developed in the future in an effort to diversify business risks. However, given its business model, the situation is expected to continue for an extended period in which its business plan depends on contracts with a limited number of partners.」
Reconfirms the risk that dependence on a small number of partners will continue over the long term, despite advancing partnership activities for subsequent pipeline products. - FY2020-Q3RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2020-Q2RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement granting Stemline exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2020-Q1RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement with Stemline granting exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2019-Q3RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement with Stemline granting exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2019-Q2RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement with Stemline granting exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2019-Q1RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement with Stemline granting exclusive worldwide rights for its development, manufacture and commercialisation. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its worldwide licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2018-Q3RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement with Stemline granting exclusive worldwide rights for its development, manufacture and commercialisation, excluding Japan, China, Taiwan and South Korea. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2018-Q2RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement with Stemline granting exclusive worldwide rights for its development, manufacture and commercialisation, excluding Japan, China, Taiwan and South Korea. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Continues to disclose the company's dependence on its licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2017RestatedAnnual report
「Given its business model, the company expects the situation to continue for an extended period in which its business plan depends on contracts with a limited number of partners.」
Reconfirms the company's dependence on a small number of partners, including Stemline, and the structure in which contract termination or amendment affects its operating results. - FY2017-Q3RestatedAnnual report
「For CBS9106, the company has entered into a licence agreement with US-based Stemline Therapeutics, Inc. granting exclusive worldwide rights for its development, manufacture and commercialisation, excluding Japan, China, Taiwan and South Korea. If this licence agreement is terminated for any reason, it will have a material impact on the company's profit or loss.」
Explicitly identifies the company's dependence on its licence agreement with Stemline and the risk of a material impact on profit or loss if the agreement is terminated. - FY2017-Q1RestatedAnnual report
「Although the company has a partnership for CBS9106, the resulting revenue is not sufficient to cover all of its operating expenses.」
Reconfirms the business structure's dependence on revenue from partners and the fact that revenue from a single partnership is insufficient to cover expenses. - FY2016First statedAnnual report
「Given its business model, the company expects the situation to continue for an extended period in which its business plan depends on contracts with a limited number of partners.」
The company identifies the impact of contract amendments, expiry and termination as risks inherent in its business model, which depends on licensing and co-development.